Lisata Therapeutics, Inc.
LSTA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000320017
No open-market purchases or sales by Lisata Therapeutics, Inc. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $3.70M in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding Lisata Therapeutics, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 29 | 34 | +5 |
| Shares | 6.27M | 7.71M | +1.45M (+23.1%) |
| Value | $10.1M | $9.41M | −$681.0K (−6.8%) |
New holders (7)
Institutions that held Lisata Therapeutics, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Sabby Management, LLC | 954,235 | $1.16M | 0.26% |
| Citadel Advisors LLC | 74,198 | $91.0K | 0.00% |
| Two Sigma Securities, LLC | 26,933 | $33.0K | 0.01% |
| Wolverine Trading, LLC | 26,031 | $30.0K | 0.00% |
| Qube Research & Technologies Ltd | 21,043 | $26.0K | 0.00% |
| Group One Trading, L.P. | 14,784 | $18.0K | 0.00% |
| Tower Research Capital LLC (TRC) | 143 | $0 | 0.00% |
Sold out (2)
Institutions that held Lisata Therapeutics, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Millennium Management LLC | 64,903 | $104.0K |
| Goldman Sachs Group Inc | 53,880 | $87.0K |